<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05022004</url>
  </required_header>
  <id_info>
    <org_study_id>BRIN-20-01</org_study_id>
    <nct_id>NCT05022004</nct_id>
  </id_info>
  <brief_title>A Therapeutic Equivalence Study in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension</brief_title>
  <official_title>Therapeutic Equivalence Study of Generic Brinzolamide 1% Ophthalmic Suspension Compared to Reference Listed Drug Azopt速 (Brinzolamide) Ophthalmic Suspension 1% in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sun Pharmaceutical Industries Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sun Pharmaceutical Industries Limited</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, Investigator-masked, multi-center, parallel group, therapeutic&#xD;
      equivalence study with clinical endpoint.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 2021</start_date>
  <completion_date type="Anticipated">March 2022</completion_date>
  <primary_completion_date type="Anticipated">March 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean difference in Intraocular Pressure of both eyes between the two treatment groups</measure>
    <time_frame>Baseline, Week 2 &amp; Week 6</time_frame>
    <description>The outcome measure is exactly what is in the OGD guidance:&#xD;
The recommended primary endpoint is the mean difference in Intraocular Pressure of both eyes between the two treatment groups at pre-specified time points.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in IOP of both eyes between the 2 treatment groups.</measure>
    <time_frame>approximately 8:00 AM. (hour 0; before the morning drop) and 10:00 AM. (hour 2) at the Day 14 (Week 2) and Day 42 (Week 6) visits</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">666</enrollment>
  <condition>Primary Open Angle Glaucoma</condition>
  <condition>Ocular Hypertension</condition>
  <arm_group>
    <arm_group_label>BRIN-20-01</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Azopt速</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Brinzolamide ophthalmic suspension</intervention_name>
    <description>dose: one drop of study medication; frequency: three times a day; route of administration: Topical ocular administration; duration of therapy: 6 weeks</description>
    <arm_group_label>BRIN-20-01</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Azopt速</intervention_name>
    <description>dose: one drop of study medication; frequency: three times a day; route of administration: Topical ocular administration; duration of therapy: 6 weeks</description>
    <arm_group_label>Azopt速</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or nonpregnant female aged 18 years or older with chronic open angle glaucoma or&#xD;
             ocular hypertension in both eyes.&#xD;
&#xD;
          -  Provide signed and dated informed consent in accordance with good clinical practice&#xD;
             and local legislation prior to any study procedure.&#xD;
&#xD;
          -  Be able and willing to follow study instructions and complete all required visits.&#xD;
&#xD;
          -  Subject requires treatment of both eyes and is able to discontinue use of all ocular&#xD;
             hypotensive medication(s) or switch ocular hypotensive medications and undergo&#xD;
             appropriate washout period.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subjects with angle closure glaucoma&#xD;
&#xD;
          -  Females who are pregnant, breast feeding, or planning a pregnancy.&#xD;
&#xD;
          -  Females of childbearing potential who do not agree to utilize an adequate form of&#xD;
             contraception.&#xD;
&#xD;
          -  Current, or past history of, severe hepatic or renal impairment&#xD;
&#xD;
          -  Current, or history within 2 months prior to baseline of, significant ocular disease&#xD;
&#xD;
          -  Functionally significant visual field loss&#xD;
&#xD;
          -  Contraindication to brinzolamide or sulfonamide therapy or known hypersensitivity to&#xD;
             any component of brinzolamide or sulfonamide therapy&#xD;
&#xD;
          -  Subjects currently in another clinical trial&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Head, Clinical Developement</last_name>
    <phone>9122 66455645</phone>
    <email>clinical.trials@sparcmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>&quot;MNTK&quot; eye microsurgery</name>
      <address>
        <city>Cheboksary</city>
        <zip>428028</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>&quot;Medical Organization &quot;Optic Center&quot;, LLC</name>
      <address>
        <city>Chelyabinsk</city>
        <zip>454000</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>&quot;MNTK&quot; eye microsurgery</name>
      <address>
        <city>Irkutsk</city>
        <zip>664017</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>&quot;MNTK&quot; eye microsurgery</name>
      <address>
        <city>Kaluga</city>
        <zip>248007</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Republican clinical ophthalmological hospital of Ministry of Health of Republic of Tatarstan named after E.V. Adamyuk</name>
      <address>
        <city>Kazan</city>
        <zip>420012</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>&quot;MNTK&quot; eye microsurgery</name>
      <address>
        <city>Khabarovsk</city>
        <zip>680033</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>&quot;Federal ophtalmology research institution n.a. Helmholtz&quot;</name>
      <address>
        <city>Moscow</city>
        <zip>105062</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>FGBOU VO &quot;Moscow Medical-Stomatology University named after A.I. Evdokimov&quot; under Ministry of Healthcare of Russian Federation</name>
      <address>
        <city>Moscow</city>
        <zip>111398</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinic &quot;Sfera&quot;</name>
      <address>
        <city>Moscow</city>
        <zip>117628</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Federal state budgetary institution &quot;State scientific center of the Russian Federation - Federal medical biophysical center named after A. I. Burnazyan&quot; FMBA of Russia</name>
      <address>
        <city>Moscow</city>
        <zip>123098</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>&quot;MNTK&quot; eye microsurgery</name>
      <address>
        <city>Moscow</city>
        <zip>127486</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MONIKI n a Vladimirskiy</name>
      <address>
        <city>Moscow</city>
        <zip>129110</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Federal budgetary healthcare institution Privolzhsky district medical center FMBA of Russia</name>
      <address>
        <city>Nizhny Novgorod</city>
        <zip>603074</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>&quot;MNTK&quot; eye microsurgery</name>
      <address>
        <city>Orenburg</city>
        <zip>460047</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institute of Human Brain of the Russian Academy of Science</name>
      <address>
        <city>Saint Petersberg</city>
        <zip>197376</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>&quot;MNTK&quot; eye microsurgery</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>192283</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>X7 Research Clinical Unit SpB</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>194156</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>&quot;The Federal State Budgetary Institution &quot; North-Western district scientific and clinical center named after L. G. Sokolov Federal Medical and Biological Agency&quot;</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>194291</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Samara medical university</name>
      <address>
        <city>Samara</city>
        <zip>443099</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Private healthcare institution railway medicine</name>
      <address>
        <city>Saratov</city>
        <zip>410004</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ufa Eye Research Institute</name>
      <address>
        <city>Ufa</city>
        <zip>450008</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinic &quot;Optimed&quot;</name>
      <address>
        <city>Ufa</city>
        <zip>453128</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ulyanovsk ophthalmology clinic &quot;Prozrenie&quot;</name>
      <address>
        <city>Ulyanovsk</city>
        <zip>432001</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>&quot;MNTK&quot; eye microsurgery</name>
      <address>
        <city>Volgograd</city>
        <zip>432001</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Russian Federation</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>August 19, 2021</study_first_submitted>
  <study_first_submitted_qc>August 19, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 26, 2021</study_first_posted>
  <last_update_submitted>November 8, 2021</last_update_submitted>
  <last_update_submitted_qc>November 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glaucoma</mesh_term>
    <mesh_term>Glaucoma, Open-Angle</mesh_term>
    <mesh_term>Ocular Hypertension</mesh_term>
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Brinzolamide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

